Abstract：
UNASSIGNED: The aim of the study was to examine the demographic, clinical features, treatment responses, and outcomes of Hodgkin lymphoma (HL) patients and to investigate the factors affecting their survival.
UNASSIGNED: A retrospective analysis was made of patients diagnosed with HL in our department between 2009 and 2019. Treatment regimen, treatment response, and follow-up times were recorded for all patients. Using these data, complete response (CR) rates, overall survival (OS), and progression-free survival (PFS) were calculated. The effects of parameters on survival were investigated with Cox regression analysis.
UNASSIGNED: Evaluation was made of 60 patients with a median age of 33.5 years [18.0-80.0] and mean follow-up duration of 29.34 ± 23.64 months. Median OS and PFS could not be reached with a mean OS of 85.6 months, and PFS of 71.7 months at the final visit. Only initial leukocyte and neurophil count were determined to have a statistically significant impact on survival (OR = 1.004; P = 0.031 vs OR = 0.996; P = 0.036).
UNASSIGNED: In HL patients, in addition to the many prognostic scoring systems, leukocyte and neutrophil count can be used as an independent prognostic parameter. Patients with higher leukocyte and lower neutrophil counts at the time of diagnosis should be managed more carefully.
UNASSIGNED: A retrospective analysis was made of patients diagnosed with HL in our department between 2009 and 2019. Treatment regimen, treatment response, and follow-up times were recorded for all patients. Using these data, complete response (CR) rates, overall survival (OS), and progression-free survival (PFS) were calculated. The effects of parameters on survival were investigated with Cox regression analysis.
UNASSIGNED: Evaluation was made of 60 patients with a median age of 33.5 years [18.0-80.0] and mean follow-up duration of 29.34 ± 23.64 months. Median OS and PFS could not be reached with a mean OS of 85.6 months, and PFS of 71.7 months at the final visit. Only initial leukocyte and neurophil count were determined to have a statistically significant impact on survival (OR = 1.004; P = 0.031 vs OR = 0.996; P = 0.036).
UNASSIGNED: In HL patients, in addition to the many prognostic scoring systems, leukocyte and neutrophil count can be used as an independent prognostic parameter. Patients with higher leukocyte and lower neutrophil counts at the time of diagnosis should be managed more carefully.
摘要：
■这项研究的目的是检查人口统计学，临床特征,治疗反应，分析霍奇金淋巴瘤(HL)患者的预后及影响其生存的因素。
■对我科2009年至2019年诊断为HL的患者进行了回顾性分析。治疗方案,治疗反应,并记录所有患者的随访时间.利用这些数据，完全反应（CR）率，总生存期（OS），计算无进展生存期（PFS）。用Cox回归分析研究各参数对生存的影响。
■对60例患者进行评估，中位年龄为33.5岁[18.0-80.0]，平均随访时间为29.34±23.64个月。平均OS为85.6个月，无法达到中位OS和PFS，最后一次访问的PFS为71.7个月。只有初始白细胞和嗜神经粒细胞计数被确定对生存有统计学意义的影响(OR=1.004;P=0.031vsOR=0.996;P=0.036)。
■在HL患者中，除了许多预后评分系统，白细胞和中性粒细胞计数可作为独立的预后参数。诊断时白细胞计数较高和中性粒细胞计数较低的患者应更仔细地管理。
■对我科2009年至2019年诊断为HL的患者进行了回顾性分析。治疗方案,治疗反应,并记录所有患者的随访时间.利用这些数据，完全反应（CR）率，总生存期（OS），计算无进展生存期（PFS）。用Cox回归分析研究各参数对生存的影响。
■对60例患者进行评估，中位年龄为33.5岁[18.0-80.0]，平均随访时间为29.34±23.64个月。平均OS为85.6个月，无法达到中位OS和PFS，最后一次访问的PFS为71.7个月。只有初始白细胞和嗜神经粒细胞计数被确定对生存有统计学意义的影响(OR=1.004;P=0.031vsOR=0.996;P=0.036)。
■在HL患者中，除了许多预后评分系统，白细胞和中性粒细胞计数可作为独立的预后参数。诊断时白细胞计数较高和中性粒细胞计数较低的患者应更仔细地管理。
